Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis

Table 1 Model parameters: baseline values, ranges and distributions for sensitivity analysis

Model parameters	Baseline	Minimum	Maximum	Distribution	Reference
Weibull survival model for OS of SG	Shape = 1.4178, Scale = 15.6718				[7]
Log-logistic survival model for OS of TPC	Shape = 1.895, Scale = 6.578				[7]
Log-normal survival model for PFS of SG	Meanlog = 1.5362, Sdlog = 1.0136				[7]
Log-logistic survival model for PFS of TPC	Shape = 2.325, Scale = 2.135				[7]
Risk for main AEs in SG
Neutropenia	0.51	0.41	0.61	Beta	[7]
Anemia	0.08	0.06	0.10	Beta	[7]
Leukopenia	0.10	0.08	0.12	Beta	[7]
Febrile neutropenia	0.06	0.05	0.07	Beta	[7]
Diarrhea	0.10	0.08	0.12	Beta	[7]
Risk for main AEs in chemotherapy
Neutropenia	0.33	0.26	0.40	Beta	[7]
Anemia	0.05	0.04	0.06	Beta	[7]
Leukopenia	0.05	0.04	0.06	Beta	[7]
Fatigue	0.05	0.04	0.06	Beta	[7]
Proportion of each regimen in TPC group
Eribulin	0.54	0.43	0.65	Beta	[7]
Vinorelbine	0.20	0.16	0.24	Beta	[7]
Capecitabine	0.13	0.10	0.16	Beta	[7]
Gemcitabine	0.12	0.10	0.14	Beta	[7]
Utility
Chemotherapy	0.860	0.790	0.920	Beta	[11]
SG	0.907	0.820	0.960	Beta	[11]
PD	0.730	0.690	0.760	Beta	[11]
Drug cost, $ per month
SG	33,277	26,622	39,932	Gamma	[17]
Eribulin	679	543	815	Gamma	[18]
Vinorelbine	714	571	857	Gamma	[18]
Capecitabine	414	331	497	Gamma	[18]
Gemcitabine	242	194	290	Gamma	[18]
Cost of AEs, $ per event
Neutropenia	740	592	888	Gamma	[19]
Anemia	1566	1253	1879	Gamma	[20]
Leukopenia	740	592	888	Gamma	[19]
Febrile neutropenia	766	613	919	Gamma	[20]
Diarrhea	743	594	892	Gamma	[20]
Fatigue	165	132	198	Gamma	[20]
Other costs, $ per event
Follow up	775	620	930	Gamma	[21]
Administration	21	17	25	Gamma	Local charge
BSC	167	134	200	Gamma	[22]
Terminal care	1981	1585	2377	Gamma	[22]

Note: SG, sacituzumab govitecan; PFS, progression-free survival; PD, progressed disease; AEs, adverse events; BSC, best supportive care

ISSN: 1478-7547